Unconquerable fortress of Januvia substance patent defeats domestic pharmaceuticals
The wall of substance patent was sturdy. Like ‘Baraclude,’ ‘Januvia,’ a diabetic treatment, succeeded in defending its substance patent from other challenges. The nullity request against the extension of the term of the patent right, filed by Jeil Pharmaceutical and Yungjin Pharm, was defeated.
...Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
